McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate

McKesson Corporation MCK opened fiscal 2027 with an earnings beat, double-digit adjusted operating profit growth and higher full-year earnings guidance. The quarter sharpened the focus on oncology, specialty distribution and GLP-1 volumes as profit drivers.

The investor question is whether those engines can keep expanding earnings while lower branded-drug pricing, cash-flow timing and the planned Medical-Surgical separation create offsets.

McKesson's Q1 Beat Reset FY27 Expectations

First-quarter adjusted earnings rose 20% to $9.93 per share, topping the Zacks Consensus Estimate of $9.44 by 5.2%. Revenues increased 8% to $105.38 billion and exceeded the consensus mark by about 1%.

Adjusted operating profit advanced 16% to $1.65 billion as growth in North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions outweighed weaker Medical-Surgical profitability. That breadth supported management's higher fiscal 2027 earnings outlook.

MCK's Oncology Platform Is Scaling Fast

Oncology & Multispecialty revenues climbed 33% to $14.22 billion, while adjusted operating profit increased 41% to $405 million. Excluding Core Ventures, revenues rose about 24% and operating profit grew about 15%, showing expansion beyond acquisitions.

The U.S. Oncology Network reached approximately 3,400 providers and treats more than 2 million patients annually. McKesson expects fiscal 2027 Oncology & Multispecialty revenue growth of 14.5%-18.5% and operating profit growth of 13.5%-17.5%.

Image Source: Zacks Investment Research

McKesson's GLP-1 Volumes Keep Distribution Relevant

GLP-1 distribution revenue reached $15 billion in the quarter, up 24% year over year and 13% sequentially. North American Pharmaceutical revenues increased 5% to $86.77 billion, while adjusted segment operating profit rose 19% to $894 million.

Lower branded pharmaceutical pricing following January 2026 wholesale acquisition cost reductions restrained revenue growth, but management said the pricing decline did not materially affect operating profit. Specialty distribution and new product launches helped offset the pressure.

Cencora, Inc. COR is seeing a similar industry theme. Its fiscal 2026 third-quarter U.S. Healthcare Solutions growth was supported by specialty products and GLP-1 class products. Cardinal Health, Inc. CAH also distributes specialty pharmaceuticals and provides related services through its Pharmaceutical and Specialty Solutions segment.

MCK's Guidance Raise Broadens the Earnings Story

McKesson raised fiscal 2027 adjusted earnings guidance to $44.20-$45.00 per share from $43.80-$44.60, implying 13%-15% growth. Companywide adjusted operating profit is expected to increase 9%-13%.

North American Pharmaceutical operating profit growth is now expected at the high end of the prior 5.5%-9.5% range. Specialty distribution, prescription volumes and new product launches therefore remain central to the earnings outlook.

McKesson's Cash Flow Outlook Adds a Key Check

First-quarter free cash flow was negative $372 million despite the stronger operating result. McKesson's working-capital needs can vary materially during the year because of inventory purchasing patterns, sales activity and timing.

Management maintained fiscal 2027 free cash flow guidance of $4.5-$4.9 billion. The company also expects about $5 billion of share repurchases for the year, making cash conversion an important checkpoint for capital returns.

MCK's Hold Signal Tempers the Earnings Momentum

The bottom line is that McKesson entered fiscal 2027 with faster profit growth and higher guidance, while oncology and GLP-1 volumes added support to the earnings mix. Cash-flow timing, pricing dynamics and portfolio execution still temper the case.

MCK currently carries a Zacks Rank #3 (Hold). It also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those scores indicate favorable characteristics across several investment styles, but they are designed to complement the Zacks Rank rather than override it. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research